A comparison of effectiveness of screening for phenylketonuria in the United States, United Kingdom and Ireland.
A study of the effectiveness of screening for phenylketonuria in the United Kingdom, Ireland, and the United States indicated that the diagnosis is more likely to be missed in the latter two countries because of the earlier age at which infants are screened. Furthermore, in the United States, diagnosis and treatment are delayed as compared with Ireland and the United Kingdom. Because test most commonly used to detect phenylketonuria is identical in all three countries, the differences in effectiveness are attributable to the way in which it is applied. In the United Kingdom, personnel and facilities have clearly defined roles and responsibilities. There is co-ordination between in-hospital and extra-hospital health care, and follow-up care of young infants in the community is assured. Greater effectiveness of screening in the United States will require a more rational organization of health services.
D000367:Age Factors; D004526:Efficiency; D005188:False Negative Reactions; D005500:Follow-Up Studies; D006285:Health Planning; D006801:Humans; D007231:Infant, Newborn; D007494:Ireland; D010649:Phenylalanine / Q000097:blood; D010661:Phenylketonurias / Q000097:blood / Q000175:diagnosis*; D013223:Statistics as Topic; D006113:United Kingdom; D014481:United States
D010649:Phenylalanine